Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02460692 · ClinicalTrials.gov registry record · Phase 2

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

A Phase 2 study, sponsored by University of California, San Diego.

Completed
Registry status
Phase 2
Development phase
131
Enrollment target

NCT02460692 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 131 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02460692, a Phase 2 study, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
Phase 2
Development phase
131 participants
Enrollment target

Study Summary

This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or placebo. An analysis will then be determined to assess the risk--benefit ratio of dronabinol and vaporized 3.7% Δ9-THC/5.6% CBD .

Interventions

  • DRUG Placebos
  • DRUG dronabinol
  • DRUG Vaporized Cannabis 3.7% THC/5.6% CBD

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2016-12
Est. Completion 2020-03-25
Phase Phase 2

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT02460692

The ClinicalTrials.gov registry entry for NCT02460692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.

NCT02460692 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02460692 about?

NCT02460692 is a clinical study titled "Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain". This study will involve treating low back pain associated with nerve injury with oral delta-9-tetrahydrocannabinol (Δ9-THC) or whole plant cannabis for eight weeks. Research subjects will consume either oral Δ9-THC (dronabinol), vaporized 3.7% Δ9-THC/5.6% CBD, or placebo. An analysis will then be de...

What is the current status of trial NCT02460692?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2016-12. Estimated completion is 2020-03-25.

What interventions are being tested in trial NCT02460692?

The interventions under investigation include: Placebos (DRUG), dronabinol (DRUG), Vaporized Cannabis 3.7% THC/5.6% CBD (DRUG).

Who is sponsoring clinical trial NCT02460692?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.